Kendall Mohler
Corporate Officer/Principal bei ALSP ORCHID ACQUISITION CORPORATION I
Aktive Positionen von Kendall Mohler
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ALSP ORCHID ACQUISITION CORPORATION I | Corporate Officer/Principal | - | - |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Corporate Officer/Principal | 01.10.2017 | - |
Neuvogen, Inc. | Direktor/Vorstandsmitglied | - | - |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Private Equity Investor | - | - |
Corporate Officer/Principal | - | - |
Karriereverlauf von Kendall Mohler
Ehemalige bekannte Positionen von Kendall Mohler
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
JUNO THERAPEUTICS INC | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2013 | 01.04.2017 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Corporate Officer/Principal | 01.01.2001 | 01.01.2002 |
ZetaRx Biosciences, Inc.
ZetaRx Biosciences, Inc. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., ZetaRx Biosciences, Inc. is a company that develops therapies for the treatment of cancers and other diseases. The company is based in Seattle, WA. The company was founded by Jack Kavanaugh. ZetaRx Biosciences was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on October 31, 2013 for $8.40 million. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.1999 | - |
Gründer | 17.11.2009 | - |
Ausbildung von Kendall Mohler
University of Kansas | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Founder | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Finance | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 7 |
---|---|
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Health Technology |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
ZetaRx Biosciences, Inc.
ZetaRx Biosciences, Inc. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., ZetaRx Biosciences, Inc. is a company that develops therapies for the treatment of cancers and other diseases. The company is based in Seattle, WA. The company was founded by Jack Kavanaugh. ZetaRx Biosciences was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on October 31, 2013 for $8.40 million. | Health Technology |
ALSP Orchid Acquisition Corp. I
ALSP Orchid Acquisition Corp. I Financial ConglomeratesFinance ALSP Orchid Acquisition Corp. I is a blank check company. It was formed for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase or other similar business combination, one or more operating businesses. The company was founded on August 31, 2021 and is headquartered in Seattle, WA. | Finance |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Neuvogen, Inc. |
- Börse
- Insiders
- Kendall Mohler
- Erfahrung